演讲嘉宾简历 / Speaker Bios以下是演讲ChinaBio® 合作论坛的演讲嘉宾名单. 主题演讲人: Greg B. Scott – President and Founder, ChinaBio® LLC
Carola Schropp, MBA, MTS - Founder and President of EBD Group
Mervyn J. Turner, PhD - Chief Strategy Officer & Senior Vice President, Worldwide Licensing & External Research, Merck & Co., Inc., USA
Alex Fowkes, JD – Executive Director and Head of R&D Business Development, Asia, Pfizer (China)
Brian Cunningham, JD - Senior Counsel and Co-Chair of Life Sciences Group, Morrison & Foerster
Kevin Chen, MBA – COO, ShangPharma Corporation
David Flores - Co-Founder, President and CEO, BioCentury Publications
Jennifer Hu, PhD – Director of Licensing & External Research, Merck & Co., USA
Michael Heerde, PhD - Director, Strategy and Business Development, Bayer Healthcare China
 Michael Heerde is currently Director Strategy and Business Development at Bayer Healthcare China. Previously as Head of Sandoz China, Michael started Novartis’ Generics business in China. He has twelve years of experience in the pharmaceutical industry and has been living in China for eight of years. Michael has a medical, sinology and business background.Wendy R. Jory, PhD, MBA - Services Segment Leader, Discovery Services, Life Technologies
Darren Ji, MD, PhD, MBA - CEO, PharmaLegacy Laboratories (Shanghai) Co., Ltd.
Kening Li, PhD, JD - Partner, Pinsent Masons LLP
R. Stephen Porter, PharmD - CSO, Medicilon/MPI Preclinical Research
Dr. R. Stephen Porter is former President, CEO and Chairman of the VDDI Pharmaceuticals. (VDDI). VDDI an international biopharmaceutical Product Development Company with principal offices located in Brentwood TN. He served as Chief Scientific Advisor to MPI Research a full service preclinical CRO. He serves as Chief Science Officer of DxRx, LLC, a molecular diagnostic service based company for infectious disease, cardiovascular and pharmacogenomic markets and he is the President of Pharmacotherapy Consultants, LLC, Brentwood, TN which engages in business development and advisory consultation services to clinical research organizations, biotech and pharmaceutical industries.Dr. Porter has over thirty years of experience in medical care delivery, research and pharmaceutical development. Dr. Porter formerly Executive Director of Medical Affairs for Therapeutic Antibodies Inc., an international biopharmaceutical firm, headquartered in Nashville, formed VDDI after 5 years at Therapeutic Antibodies Inc. (TAb) where he shepherded the development of polyclonal antibodies utilized in the treatment of envenomations, and inflammatory disease states and toxicologic emergencies. Prior to TAb he has worked at American Cyanamid Company, where he served Associate Director of Cardiovascular and Drug Metabolism in its Medical Research Division. Earlier in his career, he served as Director of Cardiovascular Pharmacology at the Likoff Cardiovascular Institute within the Hahnemann School of Medicine in Philadelphia. He has also held academic positions at the Universities of East Carolina and North Carolina Medical Schools.Dr. Porter received his doctorate in pharmacy from the University of Michigan, where he also completed his undergraduate degree and a Clinical Pharmacy residency.His professional affiliations include membership in the American Society for Clinical Pharmacology and Therapeutics, the American College of Clinical Pharmacy, Royal Society of Medicine, and Fellowship in the American College of Clinical Pharmacology. Don Qiu, PhD, MBA – Principal, ChinaBio® LLC
John Rigsbee, PhD, JD - Partner, Virtual Law Partners LLP
Xiaolin Wei, PhD, MD, MPH - Vice General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd.
Yvonne Gunsch-Wegmann, MD, MBA - Vice President, Head of Issuer and Investor Relations, SIX Swiss Exchange
Yvonne Gunsch-Wegmann has been working for SIX Swiss Exchange since 2004. She is in charge of the Issuer and Investor Relations department of SIX Swiss Exchange and its subsidiary SWX Europe, the pan-European blue chip exchange in London. Before joining SIX Swiss Exchange, Dr. Gunsch-Wegmann was in charge of Business Development at Switzerland's leading private clinic group, Hirslanden. She previously headed up a major project, promoting health in the private sector, for Prof. Dr. Felix Gutzwiller, Director of the Institute of Social and Preventive Medicine at the University of Zurich. Yvonne Gunsch-Wegmann is a doctor of medicine and has many years of clinical and scientific experience. She has studied and worked in the USA, France and Italy, gained her doctorate from the University of Zurich and also holds an Executive MBA from the University of St. Gallen. Zoe Wang, PhD, JD – Partner, Perkins Coie
Zhaohui (Zoe) Wang focuses her practice on patent infringement and validity opinions, patent prosecution, freedom-to-operate analyses, patentability analyses, technology transfers and licensing. Her work involves technologies in the fields of life sciences, nanotechnologies, data processing, and devices. She also has experience advising clients in public offerings and private placements of equity and debt securities, mergers and acquisitions, counseling companies on general corporate matters, and advising clients with respect to the Securities Act of 1933, the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act of 2002. She received her J.D. from Columbia University School of Law in 1999 and her Ph.D. in cell biology and biophysics from Duke University in 1996.
Changchun Yuan, JD - Partner, Broad & Bright
Yizhun Zhu, MD, PhD - Dean, School of Pharmacy, Fudan University
Prof. Zhu got his Bachelor of Medicine from Shanghai Second Medical University in 1989 and M.D./Ph.D. at Faculty of Medicine, University of Heidelberg, Germany in 1995. He did postdoctoral training and later as project leader at German Institute of Hypertension Research, and Institute of Pharmacology, University of Kiel, Germany and worked also at University of Washington as an visiting scholar. Before he moved to Singapore in 1998, he worked as Regional Scientific Manager (Cardiovascular drugs), Hoechst Marion Roussel Pharma AG (now Sanofil-Aventis). He moved to National University of Singapore (NUS) in 1998 and worked as Lee Kuan Yew Research Fellow/Principal Investigator and late as Associate Professor at the Dept. of Pharmacology, NUS. In 2005, Dr. Zhu was appointed as Professor of Pharmacology, Dean of School of Pharmacy and Director, Institute of Drug R&D, Fudan University. Dr. Zhu published more than 80 SCI papers with 850 citations and edited 2 books for the natural products research. He is an editor and reviewer for a series of international scientific journals. Meanwhile, he serves also as External Expert/evaluator for Centre of drug evaluation, HSA (Singapore) and SFDA (China). He holds several US, PCT and Chinese patents for the new drug discovery and extensively involves for drug R&D. One cardioprotective drug has been successfully launched in Singapore. Dr. Zhu was awarded ‘distinguished Young Scientist Grant from Natural Science Foundation of China (NSFC) in 2008 and ‘Outstanding Scientist from Shanghai’ in 2009. Wei Zhou, PhD, JD – Partner, Wilson Sonsini Goodrich & Rosati
Dr. Wei Zhou is a partner at Wilson Sonsini Goodrich & Rosati, P.C., a leading law firm focusing on technology and growth company legal issues, where he focuses on corporate and intellectual property issues facing life sciences companies in the United States and China. Prior to joining the firm, Dr. Zhou was a vice president of intellectual property and advanced technology at Affymetrix, inc. (Santa Clara, CA), where he served as general manager of the company’s China operations. During his time at Affymetrix, Wei made significant contributions to the company’s patent portfolio—ranked by the MIT Technology Review as No. 1 among pharmaceutical and biotech companies in 2002—and completed numerous scientific collaborations and partnering agreements, technology licensing agreements, commercial arrangements, and acquisitions. Before joining Affymetrix, Dr. Zhou was an attorney at Pennie & Edmonds LLP in Palo Alto, where he focused on the fields of pharmaceutical compounds, biotechnology, bioinformatics, immunology, functional genomics, drug-discovery processes, and computer software. Prior to embarking on his legal career, Dr. Zhou was a postdoctoral fellow in molecular and cellular gastroenterology at Emory University Medical School. Dr. Zhou obtained his J.D. from Stanford Law School, his Ph.D. from Virginia Tech. He is also a graduate of the General Management Program at Harvard Business School. |
白金赞助/Platinum  金牌赞助/Gold           银牌赞助/Silver      晚宴赞助 / Banquet  午餐赞助 /Lunch  官方合作伙伴/Official       支持伙伴/Supporting                      媒体伙伴/Media         主办方/Organizers   |
Greg Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded ChinaBio® Accelerator to help fund and mentor early stage life science companies in China. He is also the Founding Principal of ChinaBio® Consulting which assists U.S. and China life science companies and investors leverage the opportunities available in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of the ChinaBio® Today newsletter. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and founded and sold three high-tech firms. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.
Carola Schropp is Founder and President of EBD Group and widely recognized as one of the original proponents of our global and interconnected bio-economy. Over the past 15 years, Carola has built EBD Group into the leading partnering firm in the life science market. Under her leadership, EBD Group has grown into an organization that today spans five international partnering events on three continents that generate over 30,000 one-to-one meetings annually, and features partnering services for dozens of other events worldwide. In addition to managing the day-to-day operations of the firm, Carola is focused on bringing EBD Group partnering events to new international markets, and developing new services and technologies that foster more collaboration and growth of the biotech industry. She holds a Masters degree in Business Administration (MBA) and an MTS degree, both from Emory University, Atlanta, GA.
Dr. Mervyn Turner joined Merck Research Laboratories in 1985. Over the last 24 years, he has held many positions of increasing responsibility at Merck. In August 1999, Dr. Turner was appointed Senior Vice President, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. Dr. Turner returned from his assignment in Montreal in October 2002 to take up his current position as Senior Vice President, Worldwide Licensing and External Research. In this role, he is responsible for the oversight of all of Merck’s licensing activities, and for the management of academic relations. Through his multiple and diverse experiences in the Merck Research Laboratories, Dr. Turner has acquired a broad perspective on the issues surrounding drug discovery and development. 2004 through 2007 saw a sizeable increase in deal activity for Merck, with over 190 transactions completed. Merck has also been active in M&A, with Aton, Abmaxis, GlycoFi, Sirna and NovaCardia, all acquired to build areas of key strategic importance. Dr. Turner sees all this activity as a logical product of a cultural shift within Merck towards a more outward-facing organization.Most recently, Dr. Turner has also been appointed to the newly created role of Chief Strategy Officer for Merck & Co. Inc. where he will lead the formulation and execution of Merck's long term strategic plan and the linkage of that strategy to the business plans of Merck's Franchises, Divisions, and Functions.Dr. Turner is the author of over 80 articles in peer reviewed journals. He has served on the Editorial Board of a number of journals, and since 1998 was a member of Health Care Ventures Scientific Advisory Board.
Dr. Chan co-founded Morningside, a diversified investment group engaged primarily in private equity and venture capital investments in North America, Asia and Europe. Founded in 1986, Morningside began investing in China in 1992 and remains active in China’s internet and life science sectors. Dr. Chan is a director of publicly listed Hang Lung Group Limited, a Hong Kong property development company, and serves on the boards of several privately-held biotechnology companies, including Critical Biologics Corporation, CellCentric, Green Biologics, Stealth Peptides, and Vaccine Technologies Inc. Dr. Chan is a trustee of Fudan University in Shanghai, a governor of the New York Academy of Sciences, and sits on the advisory boards of the Johns Hopkins University - Nanjing University Center for Chinese and American Studies, The Institute of Mathematical Science of the Chinese University of Hong Kong, the International Society for Stem Cell Research, Cold Spring Harbor Conferences Asia, the Harvard China Fund, and the Physical Sciences Visiting Committee of UCLA. Dr. Chan received his BS and MS degrees in Engineering from UCLA, a Master of Science degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training at the Dana-Farber Cancer Institute.
Liam Condon was appointed as the Managing Director of Bayer HealthCare China and General Manager of Bayer Schering Pharmaceutical in March 2007. Prior to this position Liam was the Managing Director of Schering China since February 2005 and Vice-President of Bayer Healthcare since November 2006. Since 2005 both Bayer and Schering had a consistent record of being amongst the fastest growing pharmaceutical companies in China before being merged together to create a new entity. According to 2008 IMS data the newly merged company within Bayer Healthcare is today a market leader in the pharmaceutical industry in China. Liam is also the Vice-Chairman and Treasurer of RDPAC, the R&D-based Pharmaceutical Association Committee in China. Liam has over 19 years experience in the healthcare industry and has worked in Asia for 12 years. Before coming to China he was previously the Marketing, Sales and Medical Director for the Region Asia-Pacific/Middle East of Schering. In addition he spent 5 years as a Business Unit Director in Japan. Liam has a B.A. in International Marketing and Languages from Dublin City University, Ireland and also has an MBA from the Japan Management Association. He arrived in China in February 2005 and after spending 2 years in Shanghai, he now lives in Beijing with his wife and two sons. Liam speaks English, Irish, French, German, Japanese and is now working on Mandarin Chinese. He is a passionate marathon runner and has completed over 50 marathons and ultra-marathons (50-100 KM) worldwide, including the Beijing, Shanghai and Hong Kong marathons.
Dr. Du is the CEO of Hutchison Medipharma Limited (HMPL) and Chief Scientific Officer of Hutchison Chi-Med, a London AIM listed company. Dr. Du joined Hutchison Whampoa in 2001 as the executive VP for healthcare investment and was one of the key founders of Hutchison Chi-Med. She played a key role in the successful IPO of Hutchison Chi-Med in London in May 2006. In 2002, Dr. Du founded and became the founding CEO of HMPL. Since the inception of the company, HMPL has been acclaimed as one of the leading biotech firms. Dr. Du received her Ph.D. in Biochemistry from the University of Cincinnati. Prior to Hutchison, she was in Pfizer’s global strategic operation division responsible for global licensing for metabolic diseases. She started her research career at Pfizer Connecticut and led teams that involved in multiple early and late stage product development in different therapeutic areas. Two of these programs have reached to the markets. She is currently an active advisor on healthcare and biotech issues for various government agencies and research institutions in China.
Alex Fowkes obtained undergraduate degrees in science and law in Australia before joining a private practice law firm in 1994. In 1998 Alex joined Pfizer’s operations in the United Kingdom to provide legal support to its European research and development activities. In 2003 Alex moved to the Pfizer Research and Development Division (PGRD) headquarters in New London, Connecticut to lead the global legal support for PGRD’s world-wide technology transfer activities. At the end of 2006 Alex was appointed to lead PGRD’s Strategic Alliance operations in Asia and relocated to Pfizer’s Research Office in Shanghai.
Brian Cunningham is co-chair of Morrison & Foerster’s 130-lawyer Life Sciences Group. Brian brings over 25 years of experience in the biotech and pharmaceutical fields as a senior executive and as one of the top legal advisors within the biopharmaceutical industry. Prior to joining Morrison & Foerster, Brian spent seven years as Vice President, General Counsel, and Corporate Secretary at Genentech; five years as President and COO at Rigel, Inc; and most recently, two years as CEO at Trellis Bioscience, where he was also a member of the Board. He currently sits on the Board of MacuSight, a privately-held therapeutic development company, and is CEO and director of Clerigen Inc, a virtual angel financed gene therapy company. Brian also spent 12 years at Cooley Godward, where he founded and led the Life Sciences Practice and led the Health Care and Patent Practices. Brian holds a BS in engineering science and a J.D. from Washington University in St Louis, where, in law school, he was elected to the Order of the Coif and was editor of the Law Review. Most recently, he attended the Stanford University School of Business, Corporate Governance Institute, and the University of California, Haas School of Business, Global Bioexecutive Program. From 1992 to 1997, he served at various times as an Adjunct Professor of Law at the Santa Clara University School of Law. Brian is a member of the American Bar Association and the American Law Institute. He is admitted to practice in California and Missouri.
Ms. Helen Chen is a partner at L.E.K. Consulting based in Shanghai and head of L.E.K.’s China life sciences practice. She has 20 years of life science industry and consulting experience in United States and Asia, and has been practicing in China since 2000. Helen’s practice advises life sciences companies in all stages of growth, and financial investors in the commercial opportunities in the China life science sector. Helen was previously associate director of finance at Genentech in San Francisco, California, and held sales planning roles at Abbott Laboratories in North Chicago, Illinois. Helen has an honors BA from Harvard University in applied mathematics and attended the Kellogg Graduate School of Management at Northwestern University. She was a member of Board of Directors for U.S. Pharmaceutical Management Sciences Association (PMSA) from 1995 to 1997, and was honored by Who’s Who Among American Women from 1993 to 1995.
Haiyan Chen is currently a Patent Counsel at GlaxoSmithKline R&D China. She has previously worked at Fitzpatrick, Cella, Harper & Scinto, L.L.P, White & Case, L.L.P., and Morgan & Finnegan, L.L.P. She is admitted to practice in the State of New York and District of Columbia. She is also admitted to practice in the U.S. Patent and Trademark Office and U.S. District Court for the Southern District of New York. Haiyan Chen obtained her J.D. degree from Georgetown University Law Center, Washington, D.C. and Ph.D. degree from Harvard University, Cambridge, Massachusetts. Her publications include “Amgen v. Hoechst Marion Roussel: The Written Description Standard in Biotechnology Patents”, “Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1”, and “Identification of major binding proteins and substrates for the SH2-containing protein tyrosine phosphatase SHP-1 in macrophages”.
Carl Firth is currently Head of Asia Healthcare at Bank of America Merrill Lynch. Prior to joining Merrill Lynch, he worked in Singapore as Regional Business Development Director for AstraZeneca Pharmaceuticals, where he looked after business development and strategic projects across the Asia Pacific region. Previously, Carl worked in China for 3 years, where he was responsible for the commercial development of new products, and for business development activities in the China market. Carl has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence, and has over 5 years of pharmaceutical R&D experience. Carl holds a PhD from Cambridge University and an Executive MBA from London Business School.
David Flores is Co-Founder, President and CEO of BioCentury Publications, Inc., which provides business-oriented information services to a global audience of life science executives and investors from offices in the U.S. and Europe. Now in its 17th year of service, the company publishes BioCentury, the Bernstein Report on BioBusiness®, which specializes in analysis and commentary on issues affecting biopharma industry development, corporate performance and shareholder value. The company also publishes a translational science journal, SciBX: Science-Business eXchange, in a joint publishing venture with Nature Publishing Group. BioCentury's business information platform also includes BioCentury Extra, a web-based daily news service, web-based business-oriented databases, and bioindustry conferences on Wall Street, in Europe and Asia. David has devoted more than 20 years developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. David is a member of the Advisory Board of the Kellogg Center for Biotechnology at the Kellogg Graduate School of Management at Northwestern University, a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences, and a member of the Stanford Graduate School of Business Management Board. In 1996, David and BioCentury Co-Founder, Chairman & Editor-in-Chief Dr. Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, California, citing BioCentury's ongoing contributions to the industry.
Frank has been instrumental in setting up the Shanghai office of Roche Pharma Partnering. The office is strengthening Roche’s presence in the region and is mainly responsible for partnering activities in Korea, Singapore and Greater China including Taiwan and Hong Kong.Prior to taking up this post, from 2006 Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and life-cycle management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. He has been involved in about 100 transactions including product and technology deals, in- and out-licensing opportunities and also an acquisition.Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked in various research functions in Roche and at Boehringer Mannheim GmbH. Frank has a degree in chemistry from the University of Heidelberg and a Ph.D. from the Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Martinsried).His more than 40 papers have been published in well known peer-reviewed journals such as Nature Structural Biology, Journal of Molecular Biology etc. and have been cited about a thousand times. Five of them have been cited even more than a hundred times. He is also the co-author on 19 patents and patent applications.
Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc., Dr. Hu spent over three years with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics. Prior to that, she worked at Affymetrix in various capacities, including as Program Manager of Toxicology/Pharmacogenomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program. Dr. Hu got her B.S. degree in Biochemistry from Peking University; Ph.D. from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association – West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 16 years of research, management, & business development experience in biotech and pharmaceutical industry in the US.
Dr. Herrmann is a partner with WilmerHale. He specializes in life sciences industry and in the last 15 years, he represented both national and international clients in corporate transactions, particularly in public and private mergers and acquisitions, initial public offerings, private equity and venture capital transactions and intellectual property transactions. He also has experience with strategic alliances, licensing strategies, collaboration and unfair competition matters. Dr. Herrmann is a frequent speaker and lecturer, nationally and internationally, on biotechnology and pharmaceutical industry, private equity and M&A topics. He has presented lectures at Bio International, Bio Europe, Bio Equity, the Venture Capital forum and other conferences. He is also frequently recommended in the areas of M&A, Private Equity and Venture Capital, Biotechnology, Pharmaceutical and Medical Device Law by JUVE Handbook 2008/2009 .
Dr. Darren Ji is the CEO of PharmaLegacy Laboratories, a Shanghai-Zhangjiang based CRO Company focusing on providing preclinical specialty pharmacology services (www.pharmalegacy.com). Previously, Dr. Ji was the Director of Bioscience Business Development –East Asia for the Procter & Gamble Company where his overall responsibility was identifying and bringing business opportunities in bioscience-related fields from Greater China, Japan and South Korea to P&G. Dr. Ji successfully engineered a number of significant transactions between P&G and bioscience entities in the East Asia region. Two of the deals were cited by Yahoo Finance as being two outstanding activities of P&G in external alliances in 2007. Dr. Ji maintains an extensive business network in the bioscience community around the world, in particular in the US and Asia. During his extensive career at P&G, Dr. Ji had extensive experience in drug research and management and initiated and managed multiple research and development drug projects, both internally and through external partnerships, with biotech companies and research institutions in the US, Europe and Asia. As a frequent invited speaker and panelist at major biotech and pharmaceutical meetings, Dr. Ji speaks on topics of international business development in life sciences. He obtained his MD in Clinical Medicine at China Medical University, China; PhD in Biotechnology at the University of Sheffield, UK; and MBA in Entrepreneurship and Organizational Management at the University of Chicago Graduate School of Business, USA. Dr. Ji’s has been recognized and honored by various organizations including the BayHelix Group (www.bayhelix.org) where he serves on the Board Directors, the International Chinese Hard Tissue Society (www.ichts.org) (USA) where he served as President and continues as an active member of the Board of Directors, and Nankai University and Chinese Academy of Sciences where he holds a Guest Professorship.
Kewen Jin is currently General Manager of Charles River Laboratories (CRL) China preclinical service company. He was founder/CEO of BioExplorer, a preclinical CRO which formed a JV with CRL in 2007. Kewen has co-founded and served as key executive (CEO, CBO, and founding partner) for three other companies in the R&D outsourcing, drug discovery, and consulting. He served as advisor to several MNC pharma and healthcare companies, major consulting and investment firms. Previously, he was a marketing and international operation executive with Wyeth, first five years in the U.S. , then two years in Beijing. He is a Senior Advisor to Shanghai Pudong Government. He was granted the 2005 Magnolia Award, which the Shanghai government grants to individuals making major contribution to the development of Shanghai. He is a member of the Board of Directors for Bayhelix and Sino American Pharmaceutical Association (SAPA), two leading Chinese life science professional organizations. He was trained in medicine (Shanghai Jiaotong University School of Medicine), biology (Rockefeller), finance (Columbia).
Elen Leznik is a Founding Partner of VLP and the Chair of the firm’s Life Sciences Group. Ellen's practice focuses primarily on representing Life Sciences companies in intellectual property licensing and commercial transactions. Ellen has extensive experience counseling clients in a variety of industries, including biotechnology, pharmaceutical, solar energy, semiconductor, software and consumer products. She advises both private and public companies on issues related to domestic and international transactions, including research, licensing, manufacturing, collaborations, distribution and clinical trials matters. Ellen’s particular expertise is in the clinical trials area. She counsels her clients on a variety of clinical trials matters for trials conducted both in the U.S. and internationally. Prior to joining VLP, Ellen spent eight years in private practice providing legal services to Life Sciences and other technology companies, with special emphasis on international licensing transactions, collaborations, manufacturing and clinical trials. Prior to starting her private practice, Ellen served as In-House Counsel and Assistant Secretary at SUGEN, Inc., a public biotech company with its core technology in the oncology area. While at SUGEN, Ellen was responsible for the company's all legal matters (other than patents), including licensing and corporate partnering transactions, securities, clinical trials matters, employment issues, real estate and litigation matters. She served on the company’s Executive Committee and, as SUGEN's Assistant Secretary, participated in the company’s Board of Directors and Annual Shareholders meetings. Ellen began her legal career in 1995 in the Palo Alto office of Cooley Godward LLP, where she was an associate in the firm's Life Sciences practice group. Ellen served as a Board member of the Association of Corporate Counsel San Francisco Bay Area Chapter, where she also chaired the Life Sciences and Membership Committees. Ellen graduated from Stanford Law School in 1995. She received her B.B.A. in Management Information Systems (magna cum laude) and M.B.A. degrees from the University of Houston. Ellen is a member of the State Bar of California.
Dr. Li leads the Intellectual Property team of Pinsent Masons LLP in the Asia Pacific region. Prior to joining Pinsent Masons LLP, he was a shareholder in the Washington DC office of Baker Donelson Bearman Caldwell & Berkowitz PC; Counsel. He also served as Senior Counsel for E. I. Dupont de Nemours & Co. He focuses his practice on intellectual property law. He has assisted clients, ranging from start-up to Fortune 500 companies, in managing intellectual property assets as an integral part of their comprehensive competition strategy. He is experienced in formulating overall intellectual property strategy, resolving difficult freedom-to-operate obstacles, negotiating licensing agreements, and effectively utilizing existing intellectual property portfolio to strengthen client’s competitive positions. Dr. Li has substantial experience drafting and prosecuting biotechnology, chemical and pharmaceutical patents. He has participated in complex commercial and patent litigations, including proceedings before the U.S. International Trade Commission (ITC). Notably, he conducted the IP due diligence analysis for a German client in its acquisition of a California biotech company, and an Indian company in its acquisition of a major biotech company in Maryland, and helped a Maryland biopharmaceutical company in its due diligence analysis and license negotiations for a major portfolio of small molecule lead compounds. Recently, he advised multinational companies on business and IP strategies in China, including IP due diligence analysis in the acquisition of a Hong Kong-listed Chinese company. His education experience is as follows: University of Wisconsin Law School, J.D., with honors; University of Wisconsin-Madison, Ph.D. Molecular Biology; Nanjing University, China, B.S., Biology
Liu Yuwen graduated from China Pharmaceutical University with an Ms in Pharmaceutics and MBA at Fudan University, China and Norwegian Management School, and is a licensed pharmacist. She started her career with Capsugel® , a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to be QA manager in April 1998. In May 2000, following strategic expansion of Capsugel China, she transferred to New Business Development department managing new product market opportunity exploration in great China region. In May 2003, she moved to Shanghai as General Manager to set up the representative office for Perrigo Company (the world’s largest manufacturer of OTC pharmaceutical and nutritional products for the store brand market) and is taking charge of all related market development activities including JV’s in China as well as supply management in other Asia Pacific regions such as Japan, Korea, Taiwan etc. In Dec. 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by Suzhou Industrial Park, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech research and development in China. August, 2007, she became the general manager of BioBay, vice president of Suzhou Ventures Group, assistance director of Suzhou Industrial Park Science & Technology Bureau.
.jpg)
Stephen Lam, PhD, MBA joined the Hong Kong Science and Technology Parks Corporation (HKSTP) in November 2006 and is currently a Senior Manager, with the responsibility to develop the Life Sciences and Biotechnology cluster. He brings to the organization over two decades of research, management, and business development experience in the biotechnology industry. Prior to joining HKSTP, Dr. Lam served roles of increasing impact at several multi-national corporations including CIBA-Geigy, Novartis, Syngenta, and Pioneer (a DuPont Company). He also served as founder and Chief Operating Officer of Aryzun Pharmaceuticals, an early-stage drug deve lopment company focused on infectious diseases and oncology. He earned his B.A. at the University of Oregon, his MBA at Duke University, and his Ph.D. at the University of Utah. Dr. Lam is an inventor on 16 issued US patents and authored over two dozen scientific publications.
Dr. Don (Dongxu) Qiu leads ChinaBio's consulting and research activities in China. Don brings extensive management experience in the biotech industry, including research, product development, business development, operations, technology transfer, and venture capital. Dr. Qiu was previously an independent consultant to China biotechnology companies including Wex Pharmaceutical, Nanning Maple Leaf Pharmaceutical, and Beijing Joinn Pharmaceutical, the largest CRO in China. Previously, he was with MDS Capital, where he helped raise a $30M fund and participated in venture investment and technology transfer transactions. Don previously spent nine years in senior management positions with a number of biotechs, taking two compounds to the clinic. He holds a PhD in Medicinal Chemistry from Peking University and an MBA from the Richard Ivey School of Business, the University of Western Ontario.
John Rigsbee is a Partner at VLP. John's practice focuses on representing life sciences and technology companies in commercial transactions, intellectual property counseling, licensing, and general business and corporate matters. He has over 12 years experience counseling clients in a variety of industries, including biotechnology, pharmaceuticals, medical devices, semiconductor, networking, telecommunications, software and the Internet. Prior to joining VLP, John was General Counsel for Entelos, Inc., a world leader in building computer models of diseases and conducting predictive bio-simulation for the life sciences industry. At Entelos, John was responsible for all the Company’s legal affairs, including general corporate matters, commercial transactions, mergers and acquisitions, and intellectual property matters. John negotiated and closed deals with many of the world's premier pharmaceutical companies, including companies such as Pfizer, Novartis, Johnson & Johnson and Unilever. John also managed a patent portfolio consisting of 35 issued patents and over 120 pending applications worldwide. Before joining Entelos, John was corporate counsel at Jazz Pharmaceuticals, Inc., where he was responsible for providing legal advice to support R&D, licensing and acquisitions, sales and marketing, medical affairs, and clinical affairs. Prior to Jazz Pharmaceuticals, John served as corporate counsel at Tularik Inc. until its acquisition by Amgen, Inc., performing a similar range of functions. John began his legal career as an attorney with Townsend and Townsend and Crew, where he focused on commercial and patent litigation. John subsequently joined Venture Law Group, where he advised life science and technology companies on commercial transactions, intellectual property matters, licensing, and other general business and corporate matters. John earned a J.D. from University of Southern California Law Center, a Ph.D. in Chemistry from University of California, Berkeley, and a B.A. in Chemistry from Carleton College. John is a member of the State Bar of California and registered to practice before the U.S. Patent and Trademark Office.
RoseAnn Rotandaro is President and co-founder of VLP. She has represented technology companies in Silicon Valley since 1996. RoseAnn joined efforts with Craig Johnson and Andrea Chavez in a shared vision to create VLP, the world’s first top-tier virtual law firm, after founding and managing a boutique virtual firm in Palo Alto, Armor Legal Counsel, P.C. Prior to Armor Legal, RoseAnn spent several years as General Counsel for a financial software company, BenefitStreet, Inc., and a video streaming technology company, Equator Technologies, Inc. RoseAnn launched her Silicon Valley practice at the law firm of Wilson Sonsini Goodrich & Rosati where she practiced for six years. Her experience includes corporate finance, corporate governance, SEC compliance, mergers and acquisitions, venture capital and strategic transactions. RoseAnn graduated from Stanford Law School in 1995. At Stanford, RoseAnn was an editor on Stanford Law Review and participated in three moot courts, including the Jessup International Moot Court. She also received the Hilmer Oehlman, Jr. Award for Excellence in Legal Writing and Research. RoseAnn is a member of the State Bar of California and the State Bar of Alaska. In her life before lawyering, RoseAnn worked as a teacher in diverse places around the world such as the University of Science and Technology of China, the PRC’s national research university, and a public school in a Yupik Eskimo village on the Yukon-Kuskokwim Delta near the Bering Sea in Alaska. RoseAnn also served in the Peace Corps in Sierra Leone, West Africa before Sierra Leone’s civil war. She maintains a strong interest in serving communities and developing friendships worldwide. VLP supports and facilitates these values..jpg)
Dr. Victor Shi is Asia President of QIAGEN, a publicly-listed leading provider of sample and assay technologies in the field of molecular diagnostics. Dr. Shi heads QIAGEN’s commercial opera-tions and strategic development in Asia and manages an organization with around 400 em-ployees in 8 subsidiaries. Dr. Shi has over 17 years’ experience in life science business development, management and investment. Previously held positions include Managing Partner, Aura Partners (Shanghai and Hong Kong), Senior Vice President, Corporate Development, Bridge Pharmaceuticals (Menlo Park, California), Managing Director of Discovery Resources Group (Palo Alto, California), Vice President of Corporate Development at Genospectra (Fremont, California), and Director of Asia Operations at A. M. Pappas & Associates (Singapore). He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co. Dr. Shi holds Ph.D. and M.S. degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China.
Bo Wen joined The Balloch Group in 2005 and leads the company’s investment banking deal sourcing team. He has worked with the firm’s alliance partner CIBC World Markets in participating in more than 30 IPOs or follow-on offerings in the U.S. and has closed five private equity deals for Chinese clients. From 2003 to 2004, Mr. Wen served as Deputy General Manager at the Chongqing-based New Open Group, a real estate developer and investor in the education sector. Prior to that, he spent six years with CPMIEC, a leading Chinese aerospace firm, including three years overseeing the company’s business in Iran. Mr. Wen received his MBA from the Richard Ivey School of Business in Canada and graduated from Harbin Institute of Technology with dual bachelor degrees in Welding Technology and Technological English.
Dr. Wei had his medical training and then graduated from the Beijing University with with an MPH in health management. He earned his Ph.D. from the Department of Health Policy, Management and Evaluation at the University of Toronto, Canada. He has worked in the China Ministry of Health, University of Toronto, and University of Leeds with extensive research experience in primary health care and communicable disease control. As a senior research fellow in the University of Leeds, Dr. Wei has established extensive research collaborations in China and Africa, and led the communicable disease research projects funded by the DFID. He also worked as a consultant and advisor in TB and Avian Influenza for the World Health Organization and the World Bank. Dr. Wei is currently responsible for the promotion and custom services in the Base Company which oversee the largest biotech and pharma cluster in China.
Eva H. Wang is a partner in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law. Eva previously served as general counsel and vice president of legal affairs at Spreadtrum Communications, a leading NASDAQ-listed Chinese semiconductor company focused on the wireless communications market. Located in Shanghai and fluent in Mandarin, Eva was responsible for oversight of the company's compliance with U.S. securities laws and export control regulations, stock exchange rules, laws and rules set forth by the People's Republic of China, and Spreadtrum's corporate governance policies. Among many other duties, she also oversaw legal matters relating to the company's initial public offering, prepared and negotiated a variety of licensing and merger and acquisition agreements, and oversaw the implementation of the company's equity incentive plans. Prior to joining Spreadtrum, Eva was a corporate associate in Wilson Sonsini Goodrich & Rosati's Palo Alto office and Shearman & Sterling's Menlo Park office. She represented U.S. and international technology companies in venture capital financings, acquisitions, public offerings, joint ventures, and other general corporate law matters. Earlier in her career, Eva was an associate at Holland & Knight LLP in New York. Eva received her BA in Economics with Statistics from University of Western Ontario, and his JD from New York University School of Law. 
Geoff Willard is a Partner of VLP and chairs the firm’s Corporate, Securities, and Mergers and Acquisitions Group. Geoff is based in Reston, Virginia, where he represents emerging growth companies, their investors, and managers in a wide-range of corporate and commercial transactional matters. Geoff's practice focuses on mergers and acquisitions, equity and debt financings (including venture capital, strategic, seed, and angel financings), joint ventures and strategic alliances, and other corporate matters. He also advises clients on the formation and structuring of new business entities, licensing and commercial contracting matters, general employment and equity compensation matters, and corporate governance issues. His clients include both established and early-stage companies in the telecommunications, software, Internet, new media, retail, government services, healthcare, life sciences, cleantech/alternative energy, and manufacturing fields, among others. Geoff also represents venture capital, corporate, and strategic investors, as well as founders, managers and boards of start-ups, and principals of venture capital funds. Many of his clients are active in international markets and Geoff has advised on a variety of transactions involving parties or assets based or operating in China (including Hong Kong and Taiwan), Japan, India, Singapore, Australia, New Zealand, Mexico, Canada, the UK, Spain, Germany, France, and the Czech Republic, among other countries. Prior to joining VLP, Geoff was a partner with DLA Piper, a major global law firm, and an associate with Cooley Godward, one of the country's premier technology and venture capital law firms, where he engaged in a similar practice. Geoff began his legal career with the international law firm Jones Day, where his practice focused on domestic and international mergers and acquisitions, public company financings, and joint ventures and strategic alliances. During law school, Geoff spent a summer as a law clerk in the Hong Kong office of Heller Ehrman. In July 2008, Geoff was named a Mergers and Acquisitions "Rising Star" by Virginia Super Lawyers. He has been active in a variety of organizations serving the technology community, including the Mid-Atlantic Venture Association and the Northern Virginia Technology Council, and has published articles on a variety of topics. Geoff received his J.D., summa cum laude, from American University, where he was a member of the Law Review, and his B.A., cum laude, from New York University, majoring in East Asian Studies and International Politics. Geoff reads, writes, and speaks Mandarin Chinese at a basic/elementary level. He is a member of the Virginia and District of Columbia Bars. 
Richard Wang, Ph. D. MBA, currently a Director, Strategic Alliance and Collaboration for Asia since 2007, and located in the AstraZeneca's new Innovation Center China in Shanghai. Richard’s main roles include: 1) responsible for the research portfolio management and operation of the ICC, including putting management and process in place to support center strategy, reviewing projects and deliverables for performance and sustainability, managing supporting functions, 2) leading Asia strategic alliance network for AZ oncology, which involves strategy and goal setting, management of the individual centers through steering committee with country managers, alignment to global alliance strategy, identification and assessment of potential alliance centers for translational science and early clinical trial collaborations, 3) liaising and coordinating with AZ global therapeutic areas and core functions for discovery collaboration and outsourcing needs in China, as well as assessing in-licensing opportunities. Prior to AZ, Richard worked at the Discovery organization of BMS and Procter & Gamble Pharmaceuticals for total of 14 years with increasing responsibilities, the latest as associate director and project manager to lead various discovery projects transition to development and lead early clinical development projects through IND and Phase I trials.
Tao Xiong is a Partner at the Shanghai office of Broad & Bright. Tao's practice focuses primarily on representing multinational companies in cross-border mergers and acquisitions, joint ventures, private equity and venture capital investment, and general corporate matters. Tao has extensive experience counseling clients in a variety of industries, including biotechnology, pharmaceutical, information technology, and consumer products. Prior to joining Broad & Bright, Tao was an associate at O’Melveny & Myers LLP and K&L Gates LLP, both major international law firms, where her practice focused on mergers & acquisitions, private equity, securities and general corporate counseling. Tao began her legal career in 1998 as a lecturer-in-law with Renmin University of China School of Law, a top law school in China, where she taught courses on international business law. Tao received her J.D. and LL.M., both from New York University School of Law. She also received her LL.M. and LL.B., both from Renmin University of China School of Law. Tao is admitted to the National Bar of China, the State Bar of New York, and the State Bar of Pennsylvania.
Chika Yoshinaga, MD, joined Sofinnova Partners in 2007. Over her four years as Deputy General Manager at NIF SMBC Ventures, Chika invested in five life sciences companies, four based in Europe and one in the United States. Three have completed initial public offerings: Acorda Therapeutics (NASDAQ: ACOR), BioXell (SWX: BXLN), and Innate Pharma (EURONEXT: IPH). Prior to joining the venture capital industry, Chika worked as a System Engineer in the Information System Division of the Health and Science Research Institute in Yokohama, Japan. She was also a physician intern and practiced medicine at WuaTong Hospital in Shanghai, China. Chika earned an M.S. in Bio-Engineering from Yokohama National University in Japan, as well as an M.D. in Clinical Medicine from Shanghai Medical University in China.
Changchun Yuan is a partner at the Beijing Office of Broad & Bright. His major practice areas are foreign investment, M&A, general corporate, healthcare and insurance. He has over 14 years experience in advising multinational clients in various industries including a number of multinational pharmaceutical and medical device companies. He advised them on corporate governance, business negotiation, license and distribution, regulatory compliance and government affairs. Before joining Broad & Bright, Changchun was a legal consultant at Coopers & Lybrand. He then became a senior associate at an international law firm and a partner at a leading Chinese law firm in Beijing. He also served as an in-house legal counsel for the Asia Pacific Region of a multinational insurance company. Changchun began his legal career in 1985 as an assistant professor in the Chinese Academy of Social Sciences in Beijing. Changchun holds an LLM from the Chinese Academy of Social Sciences, and a JSD from Stanford Law School. He is admitted to the National Bar of China and the State Bar of New York.
Dr. Dan Zhang has more than 10 year of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO with primary operation in South East Asia and China. Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, a US research arm of Sigma-Tau S.P.A., one of the largest Italy-based pharmaceutical firms with employees of 2300. Dr. Zhang managed the firm’s entire clinical development program in North American market, including oncology, cardiovascular, CNS, and metabolic development projects, in addition to his global role of drug safety handling. Prior to his life at Sigma-Tau, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp.-the largest contract research organization (CRO) in the world, responsible for the planning and implementation of business development strategies in Greater China Area. He was also a member of Executive Operating Committee of Quintiles Transnational Corp. Dr. Zhang was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., a wholly-owned subsidiary of Quintiles Transnational Corp. Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc. His consulting services included clinical trial design, health economic studies, pricing and market-entry strategy. Over last ten years, Dr. Zhang established a strong working relationship with government and academic institutions in China. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. He was also a visiting professor at the Harbin Medical University of China. In addition, Dr. Zhang was a Ph.D. advisor and consultant for then Shanghai Medical University in the field of Pharmacoeconomic study and clinical trials. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang received his pre-med training from Beijing University and received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance. Dr. Zhang has published several papers in the fields of medical research and health economics, and is a frequent speaker at various health care-related conferences.
James J. Zhu of Perkins Coie LLP is the managing partner of the firm’s Beijing Office. James represents pharmaceutical companies like AstraZeneca, for its newly established R&D Center in China and intellectual property strategy, as well as world renowned venture capital firm Kleiner Perkins Caufield & Byers, for its investment in technology originated from China. James also helps Chinese companies license technologies originated from US companies or universities. Educated first at Fudan University in Shanghai, then earning a PhD in biology from California Institute of Technology as well as law and business degrees from Columbia University, James helps international companies protect their global IP rights and expand research capacity in the rapidly evolving but challenging IP environment in China. James has gained the reputation as the go-to source for IP and biotechnology research issues for the Sino-American life sciences industry and is very active in organizations such as the BayHelix Group, a nonprofit, invitation-only organization of leaders in the Sino-American life sciences and healthcare community, where he serves as the Chairman of the Board. James has also served as a Delegation Committee member in BIO since 2004 as a conduit between the Chinese delegation and BIO.
Copyright © 2012, ChinaBio® LLC - ChinaBio is a registered trademark of ChinaBio® LLC